Better Buy: Novavax, Inc. vs. Pfizer Inc.
Pfizer (NYSE: PFE) ranks as one of the giants of the pharmaceutical market, with a blockbuster vaccine franchise. Novavax (NASDAQ: NVAX) is only a fraction of Pfizer's size and is still at least a few years away from marketing its first vaccine -- if all goes well.
But size, and even revenue, doesn't necessarily make one stock better than another in the biopharmaceutical world. Instead, the potential for growth can make a small stock more attractive to investors than an established stock. So which of these two stocks is the better pick now? Here's how Novavax and Pfizer compare.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Stock
€25.15
-2.240%
The stock is one of the favorites of our community with 28 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 63.05% compared to the current price of 25.15 € for Pfizer Inc..
